Oxurion NV (THR):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Oxurion NV (THR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10154
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:60
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ベルギー
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Oxurion NV(Oxurion) formerly known as ThromboGenics NV, is a biotechnology company, which develops and commercializes ophthalmic and cancer medicines. The company’s ocriplasmin, a recombinant derivative of the plasmin protein, is commercialized as Jetrea in the US to treat symptomatic vitreomacular adhesion (VMA) and vitreomacular traction (VMT). Oxurion’s product pipeline includes THR-409 (ocriplasmin) under evaluation for inducing total posterior vitreous detachment in patients with non-proliferative diabetic retinopathy; THR-317 for diabetic macular edema; THR-687 and THR-149 for diabetic retinopathy. ThromboGenics spun off its oncology research in a joint venture with VIB (Flanders Institute for Biotechnology) into Oncurious NV, which focuses on the treatment of pediatric brain tumors. It has a presence in Belgium, Ireland and the US. Oxurion is headquartered in Leuven, Flemish Brabant, Belgium.

Oxurion NV (THR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Oxurion NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Oxurion NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Oxurion NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Oxurion NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Oxurion NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Oxurion NV, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Oxurion Enters into Research Agreement with Beta Therapeutics 11
ThromboGenics Forms Joint Venture with VIB 12
Licensing Agreements 13
Oncurious Enters into Licensing Agreement with VIB 13
ThromboGenics Enters into Licensing Agreement with Galapagos 14
ThromboGenics Expands Licensing Agreement with Bicycle Therapeutics 15
ThromboGenics Enters into Licensing Agreement with Grifols 16
Equity Offering 17
ThromboGenics Plans to Raise USD11.8 Million in Private Placement of Shares 17
ThromboGenics Completes Private Placement Of Shares For US$103.7 Million 18
Oxurion NV – Key Competitors 20
Oxurion NV – Key Employees 21
Oxurion NV – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Sep 06, 2018: ThromboGenics business update – H1 2018 23
May 09, 2018: ThromboGenics Business Update – Q1 2018 25
Mar 15, 2018: ThromboGenics Business Update – FY 2017 27
Sep 07, 2017: ThromboGenics Business Update – H1 2017 32
Mar 16, 2017: ThromboGenics Business Update – FY 2016 36
Corporate Communications 40
Oct 29, 2018: Oxurion names Adrienne Graves as board director 40
Nov 08, 2017: ThromboGenics Strengthens Leadership Team 41
Jun 15, 2017: Thomas Clay Appointed Chairman of the Board of Directors 42
Product News 43
04/20/2017: Thrombogenics Achieves Important Milestone In The Development Of THR-149, A Novel Plasma Kallikrein Inhibitor For Diabetic Macular Edema 43
04/04/2018: ThromboGenics Reports Initial Data from its Clinical Study evaluating THR-317 44
Product Approvals 45
Jan 17, 2017: ONCURIOUS Announces European Commission Confirmed Orphan Medicinal Product Designation for TB-403 for Medulloblastoma 45
Clinical Trials 46
Apr 27, 2018: ThromboGenics Initiates Phase 2 Clinical Study Evaluating anti-PlGF (THR-317) in combo with anti-VEGF (ranibizumab) for treatment of DME 46
Apr 06, 2018: ThromboGenics announces publication in The Journal of Medicinal Chemistry of preclinical data supporting therapeutic potential of THR-149, a plasma kallikrein inhibitor, in Diabetic Macula Edema 47
Oct 09, 2017: ThromboGenics announces publication in Experimental Eye Research of preclinical data supporting therapeutic potential of THR-317 in DR 48
Sep 27, 2017: ThromboGenics: ThromboGenics Presenting THR-687 Preclinical Data at European Association for Vision and Eye Research (EVER) Meeting 49
May 24, 2017: ThromboGenics to present THR-317 Pre-clinical Research Findings at the European Association for the Study of Diabetes, Eye Complications Study Group Meeting in Budapest, Hungary 50
Jan 10, 2017: ThromboGenics Enrolls First Patients in Phase II Clinical Study Evaluating THR-317 (Anti-PlGF) for Diabetic Macular Edema 51
Other Significant Developments 52
Sep 03, 2018: ThromboGenics becomes “Oxurion” 52
Jun 27, 2018: ThromboGenics Plans Name Change to “Oxurion” 53
Jun 21, 2018: ThromboGenics Partners with Prevent Blindness at 2018 Focus on Eye Health National Summit in Washington DC 54
Oct 20, 2017: ThromboGenics Business Update – Q3 2017 55
May 11, 2017: ThromboGenics Business Update – Q1 2017 58
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60

List of Tables
Oxurion NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Oxurion NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Oxurion NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Oxurion NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Oxurion NV, Deals By Therapy Area, 2012 to YTD 2018 9
Oxurion NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Oxurion Enters into Research Agreement with Beta Therapeutics 11
ThromboGenics Forms Joint Venture with VIB 12
Oncurious Enters into Licensing Agreement with VIB 13
ThromboGenics Enters into Licensing Agreement with Galapagos 14
ThromboGenics Expands Licensing Agreement with Bicycle Therapeutics 15
ThromboGenics Enters into Licensing Agreement with Grifols 16
ThromboGenics Plans to Raise USD11.8 Million in Private Placement of Shares 17
ThromboGenics Completes Private Placement Of Shares For US$103.7 Million 18
Oxurion NV, Key Competitors 20
Oxurion NV, Key Employees 21
Oxurion NV, Other Locations 22
Oxurion NV, Subsidiaries 22

List of Figures
Oxurion NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Oxurion NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Oxurion NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Oxurion NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Oxurion NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Oxurion NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Oxurion NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Oxurion NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Oxurion NV (THR):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Micell Technologies Inc:製品パイプライン分析
    Summary Micell Technologies Inc (Micell) is a medical device company that develops drug delivery systems for the treatment of cardiovascular diseases. The company offers product such as MiStent sirolimus eluting absorbable polymer coronary stent system, a drug-eluting stent that is designed to optim …
  • Newell Brands Inc (NWL):企業の財務・戦略的SWOT分析
    Newell Brands Inc (NWL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Croma Security Solutions Group plc (CSSG):企業の財務・戦略的SWOT分析
    Croma Security Solutions Group plc (CSSG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Siemens Healthineers AG (SHL):企業の財務・戦略的SWOT分析
    Siemens Healthineers AG (SHL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Apex Healthcare Berhad (AHEALTH):企業の財務・戦略的SWOT分析
    Apex Healthcare Berhad (AHEALTH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Braeburn Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Braeburn Inc (Braeburn), formerly Braeburn Pharmaceuticals Inc (Braeburn), is a biopharmaceutical company that develops medicines for the treatment of opioid addiction. The company’s lead product candidate CAM2038 is a weekly and monthly subcutaneous injection depot formulation of buprenorph …
  • Royal DSM NV (DSM):企業の財務・戦略的SWOT分析
    Royal DSM NV (DSM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • DCS Corporation:企業の戦略・SWOT・財務情報
    DCS Corporation - Strategy, SWOT and Corporate Finance Report Summary DCS Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • GenMark Diagnostics Inc (GNMK):企業の財務・戦略的SWOT分析
    Summary GenMark Diagnostics Inc (GenMark) is a medical device company that provides clinical testing systems. The company offers products such as XT-8 systems and ePlex systems. It offers pipeline products include eSensor 2C 19 genotyping test, eSensor HCV genotyping test, eSensor HCVg direct test, …
  • Addnode Group AB (ANOD B):企業の財務・戦略的SWOT分析
    Summary Addnode Group AB (Addnode) is an information technology company that supplies software and services for construction, design, and product data information. The company's solutions include design management solutions, process management solutions, and product lifecycle management solutions, a …
  • Standard Alliance Insurance Plc:企業の戦略・SWOT・財務情報
    Standard Alliance Insurance Plc - Strategy, SWOT and Corporate Finance Report Summary Standard Alliance Insurance Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Exxaro Resources Ltd:企業の戦略・SWOT・財務分析
    Exxaro Resources Ltd - Strategy, SWOT and Corporate Finance Report Summary Exxaro Resources Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Oil India Ltd (OIL):企業の財務・戦略的SWOT分析
    Oil India Ltd (OIL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Industrial Bank Of Korea:企業の戦略・SWOT・財務分析
    Industrial Bank Of Korea - Strategy, SWOT and Corporate Finance Report Summary Industrial Bank Of Korea - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Grupo Televisa S.A.B.:企業の戦略・SWOT・財務分析
    Grupo Televisa S.A.B. - Strategy, SWOT and Corporate Finance Report Summary Grupo Televisa S.A.B. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • DiaGenic ASA (NEL):医療機器:M&Aディール及び事業提携情報
    Summary DiaGenic ASA (DiaGenic) is a medical device company that develops and markets blood based biomarkers for early detection of Alzheimer’s disease. The company offers MCItect, ADtect and AMYtect products. Its ADtect is a blood test that helps distinguish mild to moderate range AD from the absen …
  • Ernst & Young Global Ltd:企業の戦略・SWOT・財務情報
    Ernst & Young Global Ltd - Strategy, SWOT and Corporate Finance Report Summary Ernst & Young Global Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Hitachi Metals, Ltd.:企業の戦略・SWOT・財務情報
    Hitachi Metals, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Hitachi Metals, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • NGEx Resources Inc:企業のM&A・事業提携・投資動向
    NGEx Resources Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's NGEx Resources Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Engie SA (ENGI):企業の財務・戦略的SWOT分析
    Engie SA (ENGI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆